Text Size:AAA

HER2/ErbB2 Protein, Antibody, ELISA Kit, cDNA Clone

Expression host: Human Cells
  • Slide 1
10004-HCCH-50
10004-HCCH-200
50 µg / $178
200 µg / $448
Add to Cart
Description: Active
Expression host: Human Cells
  • Slide 1
10004-H02H-50
10004-H02H-100
50 µg / $178
100 µg / $298
Add to Cart
Description: Active
Expression host: Human Cells
  • Slide 1
10004-H08H-50
10004-H08H-100
50 µg / $178
100 µg / $298
Add to Cart
Expression host: Baculovirus-Insect Cells
  • Slide 1
  • Slide 1
10004-H20B1-10
10004-H20B1-20
10 µg / $158
20 µg / $248
Add to Cart
Expression host: Human Cells
  • Slide 1
50714-M08H-50
50714-M08H-100
50 µg / $178
100 µg / $298
Add to Cart
Description: Active
Expression host: Human Cells
  • Slide 1
50714-M02H-50
50714-M02H-100
50 µg / $178
100 µg / $298
Add to Cart
Expression host: Human Cells
  • Slide 1
80079-RCCH-20
80079-RCCH-50
20 µg / $178
50 µg / $348
Add to Cart
Expression host: Human Cells
  • Slide 1
80079-R02H-50
80079-R02H-100
50 µg / $178
100 µg / $298
Add to Cart
Expression host: Human Cells
  • Slide 1
80079-R08H-50
80079-R08H-100
50 µg / $178
100 µg / $298
Add to Cart
Expression host: Human Cells
  • Slide 1
  • Slide 1
90295-C08H-50
90295-C08H-100
50 µg / $178
100 µg / $298
Add to Cart
Expression host: Human Cells
  • Slide 1
  • Slide 1
  • Slide 1
90295-C02H-50
90295-C02H-100
50 µg / $178
100 µg / $298
Add to Cart
Description: Active
Expression host: Human Cells
  • Slide 1
90020-K02H-50
90020-K02H-100
50 µg / $178
100 µg / $298
Add to Cart
Description: Active
Expression host: Human Cells
  • Slide 1
90020-K08H-50
90020-K08H-100
50 µg / $178
100 µg / $298
Add to Cart

HER2/ErbB2 Related Areas

HER2/ErbB2 Related Pathways

HER2/ErbB2 Related Product

HER2/ErbB2 Summary & Protein Information

HER2/ErbB2 Related Information

HER2/ErbB2 Background

Gene Summary: This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
General information above from NCBI
Catalytic activity: ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.
Enzyme regulation: Activated by dimerization. Not activated by EGF, TGF-alpha and amphiregulin. Interaction with PTK6 increases its intrinsic kinase activity.
Subunit structure: Homodimer. Heterodimer with EGFR, ERBB3 and ERBB4. Part of a complex with EGFR and either PIK3C2A or PIK3C2B. May interact with PIK3C2B when phosphorylated on Tyr-1196. Interacts with PRKCABP and PLXNB1. Interacts (when phosphorylated on Tyr-1248) with MEMO1. Interacts with MUC1; the interaction is enhanced by heregulin (HRG). Interacts (when phosphorylated on Tyr-1139) with GRB7 (via SH2 domain). Interacts (when phosphorylated on Tyr-1248) with ERBB2IP. Interacts with KPNB1, RANBP2, EEA1, CRM1, CLTC, PTK6, RPA94 and ACTB. Interacts with SRC (By similarity).
Subcellular location: Isoform 1: Cell membrane; Single-pass type I membrane protein. Cytoplasm, perinuclear region. Nucleus. Note=Translocation to the nucleus requires endocytosis, probably endosomal sorting and is mediated by importin beta-1/KPNB1.
Isoform 2: Cytoplasm. Nucleus.
Isoform 3: Cytoplasm. Nucleus.
Tissue specificity: Expressed in a variety of tumor tissues including primary breast tumors and tumors from small bowel, esophagus, kidney and mouth.
Post-translational: Autophosphorylated. Ligand-binding increases phosphorylation on tyrosine residues. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit. Signaling via SEMA4C promotes phosphorylation at Tyr-1248.
Involvement in disease: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. Note=The gene represented in this entry is involved in disease pathogenesis.
Glioma (GLM) [MIM:137800]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=The gene represented in this entry is involved in disease pathogenesis.
Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.
Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis. Note=The gene represented in this entry is involved in disease pathogenesis.
Gastric cancer (GASC) [MIM:613659]: A malignant disease which starts in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. The term gastric cancer or gastric carcinoma refers to adenocarcinoma of the stomach that accounts for most of all gastric malignant tumors. Two main histologic types are recognized, diffuse type and intestinal type carcinomas. Diffuse tumors are poorly differentiated infiltrating lesions, resulting in thickening of the stomach. In contrast, intestinal tumors are usually exophytic, often ulcerating, and associated with intestinal metaplasia of the stomach, most often observed in sporadic disease. Note=The gene represented in this entry is involved in disease pathogenesis.
Note=Chromosomal aberrations involving ERBB2 may be a cause gastric cancer. Deletions within 17q12 region producing fusion transcripts with CDK12, leading to CDK12-ERBB2 fusion leading to truncated CDK12 protein not in-frame with ERBB2.
Sequence similarity: Belongs to the protein kinase superfamily. Tyr protein kinase family. EGF receptor subfamily.
Contains 1 protein kinase domain.
General information above from UniProt

Human epidermal growth factor receptor 2 (HER2), also known as ErbB2, NEU, and CD340, is a type I membrane glycoprotein, and belongs to the epidermal growth factor (EGF) receptor family. HER2 protein cannot bind growth factors due to the lacking of ligand binding domain of its own and autoinhibited constitutively. However, HER2 forms a heterodimer with other ligand-bound EGF receptor family members, therefore stabilizes ligand binding and enhances kinase-mediated activation of downstream molecules. HER2 plays a key role in development, cell proliferation and differentiation. HER2 gene has been reported to associate with malignancy and a poor prognosis in numerous carcinomas, including breast, prostate, ovarian, lung cancers and so on.

HER2/ErbB2 Alternative Name

HER2/ErbB2 Related Studies

  • Krawczyk N, et al. (2009) HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor. Anticancer Res. 29(10): 4019-24.
  • Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"